127 related articles for article (PubMed ID: 22785358)
1. Tannic acid, an inhibitor of poly(ADP-ribose) glycohydrolase, sensitizes ovarian carcinoma cells to cisplatin.
Sun Y; Zhang T; Wang B; Li H; Li P
Anticancer Drugs; 2012 Oct; 23(9):979-90. PubMed ID: 22785358
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression.
Jain D; Patel N; Shelton M; Basu A; Roque R; Siede W
Cancer Chemother Pharmacol; 2010 Oct; 66(5):945-52. PubMed ID: 20101404
[TBL] [Abstract][Full Text] [Related]
3. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
4. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells.
Ong PS; Wang XQ; Lin HS; Chan SY; Ho PC
Int J Oncol; 2012 May; 40(5):1705-13. PubMed ID: 22328352
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer.
Zhang N; Wu ZM; McGowan E; Shi J; Hong ZB; Ding CW; Xia P; Di W
Cancer Sci; 2009 Dec; 100(12):2459-64. PubMed ID: 19769630
[TBL] [Abstract][Full Text] [Related]
7. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
8. Salinomycin induces apoptosis via death receptor-5 up-regulation in cisplatin-resistant ovarian cancer cells.
Parajuli B; Shin SJ; Kwon SH; Cha SD; Chung R; Park WJ; Lee HG; Cho CH
Anticancer Res; 2013 Apr; 33(4):1457-62. PubMed ID: 23564786
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADPR)polymerase inhibition and apoptosis induction in cDDP-treated human carcinoma cell lines.
Gambi N; Tramontano F; Quesada P
Biochem Pharmacol; 2008 Jun; 75(12):2356-63. PubMed ID: 18468580
[TBL] [Abstract][Full Text] [Related]
10. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
Asselin E; Mills GB; Tsang BK
Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
[TBL] [Abstract][Full Text] [Related]
12. [Relationship between expression of apoptosis-associated proteins and caspase-3 activity in cisplatin-resistant human ovarian cancer cell line].
Yang XK; Zheng F; Chen JH; Gao QL; Lu YP; Wang SX; Wang CY; Ma D
Ai Zheng; 2002 Dec; 21(12):1288-91. PubMed ID: 12520732
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
14. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
Ji T; Gong D; Han Z; Wei X; Yan Y; Ye F; Ding W; Wang J; Xia X; Li F; Hu W; Lu Y; Wang S; Zhou J; Ma D; Gao Q
Cancer Lett; 2013 Dec; 341(2):231-9. PubMed ID: 23962558
[TBL] [Abstract][Full Text] [Related]
15. PDCD6 additively cooperates with anti-cancer drugs through activation of NF-κB pathways.
Park SH; Lee JH; Lee GB; Byun HJ; Kim BR; Park CY; Kim HB; Rho SB
Cell Signal; 2012 Mar; 24(3):726-33. PubMed ID: 22142513
[TBL] [Abstract][Full Text] [Related]
16. A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian cancer cells.
Lee S; Yoon S; Kim DH
Gynecol Oncol; 2007 Feb; 104(2):338-44. PubMed ID: 17023032
[TBL] [Abstract][Full Text] [Related]
17. Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells.
Pak JH; Choi WH; Lee HM; Joo WD; Kim JH; Kim YT; Kim YM; Nam JH
Cancer Invest; 2011 Jan; 29(1):21-8. PubMed ID: 21166495
[TBL] [Abstract][Full Text] [Related]
18. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
[TBL] [Abstract][Full Text] [Related]
19. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma.
Beale PJ; Rogers P; Boxall F; Sharp SY; Kelland LR
Br J Cancer; 2000 Jan; 82(2):436-40. PubMed ID: 10646901
[TBL] [Abstract][Full Text] [Related]
20. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
